Interview with Prof. Meredith Rosenthal on the trend toward greater transparency regarding physicians’ relationships with industry. (08:52)Download Will new rules requiring drug and device companies to disclose payments to physicians and teaching hospitals have the intended effects? Disclosure's benefits are unlikely to be realized without the activation of “learned intermediaries,” such as health insurers.
No takes yet. Share an insight, caveat, or question.
Rosenthal et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: